Format

Send to

Choose Destination
Bone Marrow Transplant. 2018 May;53(5):609-616. doi: 10.1038/s41409-017-0084-2. Epub 2018 Jan 24.

The Japan Marrow Donor Program, 25 years of experience in achieving 20,000 bone marrow transplantations: organization structure, activity, and financial basis.

Author information

1
Japan Marrow Donor Program, 3-19, Kandanishiki-cho, Chiyoda-ku, Tokyo, 1010054, Japan. hi.saito@nnh.hosp.go.jp.
2
Japan Marrow Donor Program, 3-19, Kandanishiki-cho, Chiyoda-ku, Tokyo, 1010054, Japan.
3
Department of Cell Transplantation and Regenerative Medicine, Tokai University School of Medicine, Tokyo, Japan.
4
Division of Hematology, Department of Medicine, Keio Uinversity School of Medicine, Tokyo, Japan.
5
Technical Department, Japanese Red Cross Society Blood Service Headquarters, Tokyo, Japan.
6
Department of Hematology, Kanagawa Cancer Center, Tokyo, Japan.

Abstract

The Japan Marrow Donor Program (JMDP), established in 1991, has continued to grow in its capacity to facilitate unrelated bone marrow (BMT) and peripheral blood stem cell transplantation (PBSCT) for the past 25 years in Japan. The current donor pool is 463,465 (as of 31 December 2016) and 20,237 transplants were performed with the help of the Japanese Red Cross, government, and supporters. As JMDP introduced PBSCT in 2010, the vast majority of transplants are BMT. All donors are fully typed for HLA-A, B, C, and DR. The peak age of registered donors is around 40 years. The 8/8 HLA-matched donors are found in our registry for 96% of the patients and 54% of the patients receive a transplant. The median time between the initiation of donor search and the transplantation is approximately 122 days. The median interval between the initiation of donor search and identification of the first potential donor is 40 days. The most common diseases for which unrelated BMT/PBSCT is indicated are acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), myelodysplastic syndrome (MDS), and malignant lymphoma. In recent years we have seen a marked increase in elderly patients who received BMT.

PMID:
29367710
DOI:
10.1038/s41409-017-0084-2
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center